OAJ
UTHR icon

Ogorek Anthony Joseph’s United Therapeutics UTHR Stock Holding History

Ogorek Anthony Joseph’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Hold
2
– – ﹤0.01% 628
2026
Q1 		$1K Hold
2
– – ﹤0.01% 625
2025
Q4 		$0 Hold
2
– – ﹤0.01% 698
2025
Q3 		$0 Hold
2
– – ﹤0.01% 692
2025
Q2 		$0 Hold
2
– – ﹤0.01% 695
2025
Q1 		$0 Buy
+2
New +$685 ﹤0.01% 683

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Ogorek Anthony Joseph's UTHR Position: Q2 2026 in Review

Ogorek Anthony Joseph held its United Therapeutics (UTHR) position steady in Q2 2026 at 2 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #628.

Ogorek Anthony Joseph first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Ogorek Anthony Joseph held 2 shares of United Therapeutics worth $1K as of Q2 2026.
  • Ogorek Anthony Joseph left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Ogorek Anthony Joseph's portfolio in Q2 2026, its #628 holding.
  • Ogorek Anthony Joseph first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Ogorek Anthony Joseph's 13F filing for Q2 2026, filed 7 Aug 2026.